The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care

Cytotherapy. 2014 Feb;16(2):149-59. doi: 10.1016/j.jcyt.2013.11.010.

Abstract

Adoptive immunotherapy-in particular, T-cell therapy-has recently emerged as a useful strategy with the potential to overcome many of the limitations of antiviral drugs for the treatment of viral complications after hematopietic stem cell transplantation. In this review, we briefly summarize the current methods for virus-specific T-cell isolation or selection and we report results from clinical trials that have used these techniques, focusing specifically on the strategies aimed to broaden the application of this technology.

Keywords: T cell; immunotherapy; stem cell transplantation; virus.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Antigens, Viral / immunology
  • Clinical Trials as Topic
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Immunotherapy, Adoptive / trends
  • Postoperative Complications / immunology*
  • Postoperative Complications / prevention & control
  • Standard of Care
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / transplantation
  • Transplantation, Homologous
  • Virus Diseases / immunology*
  • Virus Diseases / prevention & control

Substances

  • Antigens, Viral